Review



islet il 1β immunoreactivity  (ProSci Incorporated)


Bioz Verified Symbol ProSci Incorporated is a verified supplier
Bioz Manufacturer Symbol ProSci Incorporated manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    ProSci Incorporated islet il 1β immunoreactivity
    IHC for <t>insulin,</t> <t>IL-1β,</t> and amyloid in subjects with and without CF. Representative staining of pancreas specimens from subjects in non-CF control (A–D), CF-no DM (E–H), and CFRD (I–L) groups, identifying islet β-cells using IHC for insulin (brown in A, E, and I and red in D, H, and L), IL-1β (brown; images shown from two subjects per group in B and C, F and G, and J and K), and amyloid (visualized by thioflavin S [ThioS] histochemistry; green in D, H, and L). Quantitation of the proportion of islets positive for IL-1β (M) and amyloid (N). Islet IL-1β positivity was increased in CF-no DM and CFRD subjects compared with age-matched non-CF control subjects, whereas islet amyloid deposition was only increased in CFRD subjects. Scale bar = 50 µm.
    Islet Il 1β Immunoreactivity, supplied by ProSci Incorporated, used in various techniques. Bioz Stars score: 93/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/islet il 1β immunoreactivity/product/ProSci Incorporated
    Average 93 stars, based on 6 article reviews
    islet il 1β immunoreactivity - by Bioz Stars, 2026-03
    93/100 stars

    Images

    1) Product Images from "Islet Interleukin-1β Immunoreactivity Is an Early Feature of Cystic Fibrosis That May Contribute to β-Cell Failure"

    Article Title: Islet Interleukin-1β Immunoreactivity Is an Early Feature of Cystic Fibrosis That May Contribute to β-Cell Failure

    Journal: Diabetes Care

    doi: 10.2337/dc17-1387

    IHC for insulin, IL-1β, and amyloid in subjects with and without CF. Representative staining of pancreas specimens from subjects in non-CF control (A–D), CF-no DM (E–H), and CFRD (I–L) groups, identifying islet β-cells using IHC for insulin (brown in A, E, and I and red in D, H, and L), IL-1β (brown; images shown from two subjects per group in B and C, F and G, and J and K), and amyloid (visualized by thioflavin S [ThioS] histochemistry; green in D, H, and L). Quantitation of the proportion of islets positive for IL-1β (M) and amyloid (N). Islet IL-1β positivity was increased in CF-no DM and CFRD subjects compared with age-matched non-CF control subjects, whereas islet amyloid deposition was only increased in CFRD subjects. Scale bar = 50 µm.
    Figure Legend Snippet: IHC for insulin, IL-1β, and amyloid in subjects with and without CF. Representative staining of pancreas specimens from subjects in non-CF control (A–D), CF-no DM (E–H), and CFRD (I–L) groups, identifying islet β-cells using IHC for insulin (brown in A, E, and I and red in D, H, and L), IL-1β (brown; images shown from two subjects per group in B and C, F and G, and J and K), and amyloid (visualized by thioflavin S [ThioS] histochemistry; green in D, H, and L). Quantitation of the proportion of islets positive for IL-1β (M) and amyloid (N). Islet IL-1β positivity was increased in CF-no DM and CFRD subjects compared with age-matched non-CF control subjects, whereas islet amyloid deposition was only increased in CFRD subjects. Scale bar = 50 µm.

    Techniques Used: Staining, Control, Quantitation Assay

    Subject characteristics and islet morphometric analyses in individuals with CF, subdivided according to diabetes and lung transplant status
    Figure Legend Snippet: Subject characteristics and islet morphometric analyses in individuals with CF, subdivided according to diabetes and lung transplant status

    Techniques Used:



    Similar Products

    islet il 1β immunoreactivity  (ProSci Incorporated)
    93
    ProSci Incorporated islet il 1β immunoreactivity
    IHC for <t>insulin,</t> <t>IL-1β,</t> and amyloid in subjects with and without CF. Representative staining of pancreas specimens from subjects in non-CF control (A–D), CF-no DM (E–H), and CFRD (I–L) groups, identifying islet β-cells using IHC for insulin (brown in A, E, and I and red in D, H, and L), IL-1β (brown; images shown from two subjects per group in B and C, F and G, and J and K), and amyloid (visualized by thioflavin S [ThioS] histochemistry; green in D, H, and L). Quantitation of the proportion of islets positive for IL-1β (M) and amyloid (N). Islet IL-1β positivity was increased in CF-no DM and CFRD subjects compared with age-matched non-CF control subjects, whereas islet amyloid deposition was only increased in CFRD subjects. Scale bar = 50 µm.
    Islet Il 1β Immunoreactivity, supplied by ProSci Incorporated, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/islet il 1β immunoreactivity/product/ProSci Incorporated
    Average 93 stars, based on 1 article reviews
    islet il 1β immunoreactivity - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier
    il 1β immunoreactivity  (ProSci Incorporated)
    93
    ProSci Incorporated il 1β immunoreactivity
    IHC for <t>insulin,</t> <t>IL-1β,</t> and amyloid in subjects with and without CF. Representative staining of pancreas specimens from subjects in non-CF control (A–D), CF-no DM (E–H), and CFRD (I–L) groups, identifying islet β-cells using IHC for insulin (brown in A, E, and I and red in D, H, and L), IL-1β (brown; images shown from two subjects per group in B and C, F and G, and J and K), and amyloid (visualized by thioflavin S [ThioS] histochemistry; green in D, H, and L). Quantitation of the proportion of islets positive for IL-1β (M) and amyloid (N). Islet IL-1β positivity was increased in CF-no DM and CFRD subjects compared with age-matched non-CF control subjects, whereas islet amyloid deposition was only increased in CFRD subjects. Scale bar = 50 µm.
    Il 1β Immunoreactivity, supplied by ProSci Incorporated, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/il 1β immunoreactivity/product/ProSci Incorporated
    Average 93 stars, based on 1 article reviews
    il 1β immunoreactivity - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier
    il-1β immunoreactivity  (Genzyme)
    90
    Genzyme il-1β immunoreactivity
    IHC for <t>insulin,</t> <t>IL-1β,</t> and amyloid in subjects with and without CF. Representative staining of pancreas specimens from subjects in non-CF control (A–D), CF-no DM (E–H), and CFRD (I–L) groups, identifying islet β-cells using IHC for insulin (brown in A, E, and I and red in D, H, and L), IL-1β (brown; images shown from two subjects per group in B and C, F and G, and J and K), and amyloid (visualized by thioflavin S [ThioS] histochemistry; green in D, H, and L). Quantitation of the proportion of islets positive for IL-1β (M) and amyloid (N). Islet IL-1β positivity was increased in CF-no DM and CFRD subjects compared with age-matched non-CF control subjects, whereas islet amyloid deposition was only increased in CFRD subjects. Scale bar = 50 µm.
    Il 1β Immunoreactivity, supplied by Genzyme, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/il-1β immunoreactivity/product/Genzyme
    Average 90 stars, based on 1 article reviews
    il-1β immunoreactivity - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    IHC for insulin, IL-1β, and amyloid in subjects with and without CF. Representative staining of pancreas specimens from subjects in non-CF control (A–D), CF-no DM (E–H), and CFRD (I–L) groups, identifying islet β-cells using IHC for insulin (brown in A, E, and I and red in D, H, and L), IL-1β (brown; images shown from two subjects per group in B and C, F and G, and J and K), and amyloid (visualized by thioflavin S [ThioS] histochemistry; green in D, H, and L). Quantitation of the proportion of islets positive for IL-1β (M) and amyloid (N). Islet IL-1β positivity was increased in CF-no DM and CFRD subjects compared with age-matched non-CF control subjects, whereas islet amyloid deposition was only increased in CFRD subjects. Scale bar = 50 µm.

    Journal: Diabetes Care

    Article Title: Islet Interleukin-1β Immunoreactivity Is an Early Feature of Cystic Fibrosis That May Contribute to β-Cell Failure

    doi: 10.2337/dc17-1387

    Figure Lengend Snippet: IHC for insulin, IL-1β, and amyloid in subjects with and without CF. Representative staining of pancreas specimens from subjects in non-CF control (A–D), CF-no DM (E–H), and CFRD (I–L) groups, identifying islet β-cells using IHC for insulin (brown in A, E, and I and red in D, H, and L), IL-1β (brown; images shown from two subjects per group in B and C, F and G, and J and K), and amyloid (visualized by thioflavin S [ThioS] histochemistry; green in D, H, and L). Quantitation of the proportion of islets positive for IL-1β (M) and amyloid (N). Islet IL-1β positivity was increased in CF-no DM and CFRD subjects compared with age-matched non-CF control subjects, whereas islet amyloid deposition was only increased in CFRD subjects. Scale bar = 50 µm.

    Article Snippet: Islet IL-1β Immunoreactivity Is Seen Even in Very Young Subjects With CF We next analyzed islet IL-1β immunoreactivity (using the ProSci antibody) in the subset of pediatric CF subjects <10 years of age, the currently recommended age to begin screening CF patients for CFRD with oral glucose tolerance tests ( 5 ).

    Techniques: Staining, Control, Quantitation Assay

    Subject characteristics and islet morphometric analyses in individuals with CF, subdivided according to diabetes and lung transplant status

    Journal: Diabetes Care

    Article Title: Islet Interleukin-1β Immunoreactivity Is an Early Feature of Cystic Fibrosis That May Contribute to β-Cell Failure

    doi: 10.2337/dc17-1387

    Figure Lengend Snippet: Subject characteristics and islet morphometric analyses in individuals with CF, subdivided according to diabetes and lung transplant status

    Article Snippet: Islet IL-1β Immunoreactivity Is Seen Even in Very Young Subjects With CF We next analyzed islet IL-1β immunoreactivity (using the ProSci antibody) in the subset of pediatric CF subjects <10 years of age, the currently recommended age to begin screening CF patients for CFRD with oral glucose tolerance tests ( 5 ).

    Techniques: